Cambridge Healthtech Institute’s Third Annual Immuno-Oncology Summit Europe returns to the heart of London’s Canary Wharf for a full week of cutting-edge science and discussion. Through three back-to-back conference tracks, delegates have the opportunity to hear from the research teams at the forefront of the rapidly developing field of cancer biotherapeutics. The first track, Adoptive T-Cell Therapy, will highlight advances in next-generation CAR-Ts, TCRs, and TILs, and approaches for engagement of the innate immune system. The track will present genetic engineering technologies for T cells, preclinical models, and production, and focus on specificity, off-target toxicity and safety. A dedicated track on Combination Immunotherapy will follow with a review of strategies and approaches for designing rational combination immunotherapies. This track will provide case studies of immune modulator combinations, combinations of checkpoint inhibitors with other modalities, and biomarker-and mechanism-based selection of IO combinations. The final track of the week, Immunomodulatory Antibodies, will present advances with checkpoint inhibitors, agonistic receptor engagement, NK and macrophage activation, bispecifics, and Fc-engineering technologies. Challenges in tumours unresponsive to checkpoint blockade will be addressed.